does glp-1 lower blood pressure glp 1 cardiovascular benefits Beyond the Scale: Surprising of Peptides at Aglow Semaglutide Shows Secondary Cardiovascular Prevention – A Comprehensive Review of the

Obesity Landscape - Final Thoughts Dosing The GLP-1 RA obesity market, driven by injectables, has seen historic levels of success, and near-term entrants are likely to provide more dosing options within the GLP-1 or GLP-1/GIP class Weight Loss Novel drugs in development are likely to be approved within the next 5 years, with improved weight loss efficacy compared to what Wegovy and Zepbound have demonstrated Body Comp The coming years will likely see increased data on muscle preservation and the quality of weight loss with novel MoAs, even if used in combination with GLP-1/incretin-targeting agents As the obesity market matures, how will patients think about the tradeoffs between efficacy, safety, and dosing/convenience with the availability of new drugs and more data

Ter Horst KW, Serlie MJ

Overall, the effects of insulin degludec were similar to those observed with human insulin, which were probably secondary to maternal hypoglycemia

First, individuals with pre-existing kidney disease should discuss creatine supplementation with their healthcare provider